Ublituximab — TG Therapeutics’ potential blockbuster infusion for multiple sclerosis (MS) — is probably more clinically effective than the approved oral disease-modifying therapies but wouldn’t be cost-effective if priced the…
The European Medicines Agency’s (EMA) human medicines committee gave a thumbs-up to 10 new drugs at its latest monthly meeting. Source: Drug Industry Daily
Milestone Pharmaceuticals’ investigational nasal spray etripamil claimed a phase 3 win, with topline data indicating that abnormal heart rhythms normalized in 64 percent of patients with paroxysmal supraventricular tachycardia (PSVT)…
In a trio of guidances released Monday, the FDA laid out new recommendations for research on cancer drugs, including how to develop drugs for acute myeloid leukemia (AML), how to…
A failure to withdraw marketing approval of Covis’ preterm birth drug Makena would amount to a failure of FDA’s Accelerated Approval pathway, according to Peter Stein, director of the agency’s…
The U.S. Department of Justice (DOJ) announced that three members of a Miami-based research center have been charged for allegedly running a years-long scheme to falsify clinical trial data for…
The Department of Health and Human Services (HHS) will have to come up with a plan to force down the cost of prescription drugs under an executive order signed by…
In the wake of the reauthorization of the Generic Drug User Fee Amendments (GDUFA), the FDA has updated its guidance for prior approval supplements (PAS) and amendments for abbreviated new…
The FDA rapped Fresenius Kabi for batch discrepancies and contamination issues, among other quality lapses, following an inspection of its Melrose Park, Ill., facility. Source: Drug Industry Daily
Less that a third of regulatory actions spurred by safety signals in the FDA Adverse Event Reporting System (FAERS) weresupported by published studies, with most actions relying instead on case…